ArticleCureus2025
Sarcomatoid Variant of Hepatocellular Carcinoma: Rare and Deadly.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcomatoid hepatocellular carcinoma (SHCC) is a rare and aggressive subtype of hepatocellular carcinoma (HCC), often associated with poor prognosis due to its late presentation, high metastatic potential, and resistance to treatment. We report the case of a 69-year-old male with newly diagnosed hepatitis C infection who presented with right hypochondrial pain, weight loss, and constitutional symptoms. Imaging revealed multiple hepatic masses, portal vein thrombosis, and extensive lymphadenopathy. Biopsy of a dominant liver lesion confirmed SHCC, with histopathological features of atypical spindle cells and immunohistochemical positivity for cytokeratin (CK), glutamine synthetase, and heat shock protein-70 (HSP-70), confirming hepatocellular lineage. Given the unresectable nature of the disease and its advanced stage at diagnosis, the patient received doxorubicin-based chemotherapy as a palliative measure; however, despite initial symptomatic improvement, the overall survival was limited to 5.5 months from the time of initial presentation. This case highlights the diagnostic and therapeutic challenges of SHCC and underscores the importance of early histological confirmation, as well as the urgent need to explore novel systemic therapies for this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.